DE102004025986A1 - Steroid-Prodrugs mit androgener Wirkung - Google Patents

Steroid-Prodrugs mit androgener Wirkung Download PDF

Info

Publication number
DE102004025986A1
DE102004025986A1 DE102004025986A DE102004025986A DE102004025986A1 DE 102004025986 A1 DE102004025986 A1 DE 102004025986A1 DE 102004025986 A DE102004025986 A DE 102004025986A DE 102004025986 A DE102004025986 A DE 102004025986A DE 102004025986 A1 DE102004025986 A1 DE 102004025986A1
Authority
DE
Germany
Prior art keywords
group
sulfamoylbenzoate
oxo
hydroxy
sulphamoylbenzoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE102004025986A
Other languages
German (de)
English (en)
Inventor
Ralf Dr. Wyrwa
Sven Ring
Peter Dr. Droescher
Alexander Dr. Hillisch
Walter Dr. Elger
Birgitt Schneider
Gudrun Reddersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to DE102004025986A priority Critical patent/DE102004025986A1/de
Priority to EA200602049A priority patent/EA200602049A1/ru
Priority to PCT/EP2005/005256 priority patent/WO2005113575A1/de
Priority to BRPI0510136-0A priority patent/BRPI0510136A/pt
Priority to EP05742657A priority patent/EP1747229A1/de
Priority to CNA200580016339XA priority patent/CN1993375A/zh
Priority to CA002564963A priority patent/CA2564963A1/en
Priority to MXPA06013469A priority patent/MXPA06013469A/es
Priority to AU2005245568A priority patent/AU2005245568A1/en
Priority to JP2007517047A priority patent/JP2007538026A/ja
Priority to GT200500122A priority patent/GT200500122A/es
Priority to TW094116504A priority patent/TW200613317A/zh
Priority to PA20058633601A priority patent/PA8633601A1/es
Priority to ARP050102084A priority patent/AR049547A1/es
Priority to UY28911A priority patent/UY28911A1/es
Priority to PE2005000556A priority patent/PE20060271A1/es
Priority to SV2005002123A priority patent/SV2006002123A/es
Publication of DE102004025986A1 publication Critical patent/DE102004025986A1/de
Priority to IL179293A priority patent/IL179293A0/en
Priority to EC2006007028A priority patent/ECSP067028A/es
Priority to CR8785A priority patent/CR8785A/es
Priority to NO20065885A priority patent/NO20065885L/no
Priority to ZA200610769A priority patent/ZA200610769B/xx
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE102004025986A 2004-05-21 2004-05-21 Steroid-Prodrugs mit androgener Wirkung Ceased DE102004025986A1 (de)

Priority Applications (22)

Application Number Priority Date Filing Date Title
DE102004025986A DE102004025986A1 (de) 2004-05-21 2004-05-21 Steroid-Prodrugs mit androgener Wirkung
EA200602049A EA200602049A1 (ru) 2004-05-21 2005-05-10 Пролекарства стероидов с андрогенным действием
PCT/EP2005/005256 WO2005113575A1 (de) 2004-05-21 2005-05-10 Steroid-prodrugs mit androgener wirkung
BRPI0510136-0A BRPI0510136A (pt) 2004-05-21 2005-05-10 prodrogas esteróides com efeito androgênico
EP05742657A EP1747229A1 (de) 2004-05-21 2005-05-10 Steroid-prodrugs mit androgener wirkung
CNA200580016339XA CN1993375A (zh) 2004-05-21 2005-05-10 具有雄激素作用的甾类前药
CA002564963A CA2564963A1 (en) 2004-05-21 2005-05-10 Steroid prodrugs with androgenic effect
MXPA06013469A MXPA06013469A (es) 2004-05-21 2005-05-10 Profarmacos de esteroides con accion androgenica.
AU2005245568A AU2005245568A1 (en) 2004-05-21 2005-05-10 Steroid prodrugs with androgenic effect
JP2007517047A JP2007538026A (ja) 2004-05-21 2005-05-10 アンドロゲン作用を有するステロイドプロドラッグ
PE2005000556A PE20060271A1 (es) 2004-05-21 2005-05-20 Profarmacos de esteroides con accion androgenica
GT200500122A GT200500122A (es) 2004-05-21 2005-05-20 Profarmacos de esteroides con accion androgenica
TW094116504A TW200613317A (en) 2004-05-21 2005-05-20 Steroid prodrugs with androgenic action
PA20058633601A PA8633601A1 (es) 2004-05-21 2005-05-20 Profarmacos de esteroides con accion androgenica
ARP050102084A AR049547A1 (es) 2004-05-21 2005-05-20 Profarmacos de esteroides con accion androgenica
UY28911A UY28911A1 (es) 2004-05-21 2005-05-20 Profármacos de esteroides con acción androgénica
SV2005002123A SV2006002123A (es) 2004-05-21 2005-05-23 Profarmacos de esteroides con accion androgenica ref. p-sv-78.334/msu
IL179293A IL179293A0 (en) 2004-05-21 2006-11-15 Steroid prodrugs with androgenic effect
EC2006007028A ECSP067028A (es) 2004-05-21 2006-11-27 Profármacos de esteroides con acción androgénica
CR8785A CR8785A (es) 2004-05-21 2006-12-05 Profarmacos de esteroides con accion androgenica
NO20065885A NO20065885L (no) 2004-05-21 2006-12-19 Steroide prolegemidler med androgen virkning
ZA200610769A ZA200610769B (en) 2004-05-21 2006-12-20 Steroid prodrugs with androgenic effect

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004025986A DE102004025986A1 (de) 2004-05-21 2004-05-21 Steroid-Prodrugs mit androgener Wirkung

Publications (1)

Publication Number Publication Date
DE102004025986A1 true DE102004025986A1 (de) 2005-12-15

Family

ID=34968657

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102004025986A Ceased DE102004025986A1 (de) 2004-05-21 2004-05-21 Steroid-Prodrugs mit androgener Wirkung

Country Status (22)

Country Link
EP (1) EP1747229A1 (es)
JP (1) JP2007538026A (es)
CN (1) CN1993375A (es)
AR (1) AR049547A1 (es)
AU (1) AU2005245568A1 (es)
BR (1) BRPI0510136A (es)
CA (1) CA2564963A1 (es)
CR (1) CR8785A (es)
DE (1) DE102004025986A1 (es)
EA (1) EA200602049A1 (es)
EC (1) ECSP067028A (es)
GT (1) GT200500122A (es)
IL (1) IL179293A0 (es)
MX (1) MXPA06013469A (es)
NO (1) NO20065885L (es)
PA (1) PA8633601A1 (es)
PE (1) PE20060271A1 (es)
SV (1) SV2006002123A (es)
TW (1) TW200613317A (es)
UY (1) UY28911A1 (es)
WO (1) WO2005113575A1 (es)
ZA (1) ZA200610769B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE102005057408A1 (de) * 2005-11-30 2007-05-31 Bayer Schering Pharma Ag Sulfamoylsulfonat-Prodrugs
CN101708338B (zh) * 2008-12-26 2014-06-04 中国人民解放军军事医学科学院放射与辐射医学研究所 含甾体结构的前药及其高度分散制剂
CN102964417A (zh) * 2012-11-30 2013-03-13 华中药业股份有限公司 17-羟基四氢吡喃醚甾族化合物的合成方法
CN107556258B (zh) * 2017-08-22 2021-06-04 湖北江田精密化学有限公司 一种4-氨基-2-氯-5(1h-四唑基-5)苯磺酰胺的制备方法
EP3533619A1 (en) * 2018-03-02 2019-09-04 Basf Se Heat sensitive recording material and color developer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001234A (en) * 1987-04-16 1991-03-19 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
DE19712488A1 (de) * 1997-03-25 1998-10-01 Knoell Hans Forschung Ev Steroidsulfamate, Verfahren zu ihrer Herstellung und Anwendung derselben
US5866603A (en) * 1994-11-17 1999-02-02 Duquesne University Of The Holy Ghost Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH545316A (de) * 1970-07-17 1973-12-15 Hoffmann La Roche Verfahren zur Herstellung von Acylderivaten
DE10027887A1 (de) * 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001234A (en) * 1987-04-16 1991-03-19 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5866603A (en) * 1994-11-17 1999-02-02 Duquesne University Of The Holy Ghost Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use
DE19712488A1 (de) * 1997-03-25 1998-10-01 Knoell Hans Forschung Ev Steroidsulfamate, Verfahren zu ihrer Herstellung und Anwendung derselben

Also Published As

Publication number Publication date
WO2005113575A1 (de) 2005-12-01
GT200500122A (es) 2006-01-24
CA2564963A1 (en) 2005-12-01
IL179293A0 (en) 2007-03-08
SV2006002123A (es) 2006-02-15
BRPI0510136A (pt) 2007-10-02
JP2007538026A (ja) 2007-12-27
CN1993375A (zh) 2007-07-04
AU2005245568A1 (en) 2005-12-01
PE20060271A1 (es) 2006-05-25
UY28911A1 (es) 2005-12-30
EA200602049A1 (ru) 2007-06-29
NO20065885L (no) 2006-12-19
CR8785A (es) 2007-02-05
EP1747229A1 (de) 2007-01-31
ECSP067028A (es) 2006-12-29
PA8633601A1 (es) 2006-07-03
AR049547A1 (es) 2006-08-16
TW200613317A (en) 2006-05-01
ZA200610769B (en) 2008-08-27
MXPA06013469A (es) 2007-01-23

Similar Documents

Publication Publication Date Title
EP1448591B1 (de) 17alpha-alkyl-17beta-oxy-estratriene und zwischenprodukte zu deren herstellung, verwendung der 17alpha-alkyl-17beta-oxy-estratriene zur herstellung von arzneimitteln sowie pharmazeutische präparate
EP2456781B1 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9 (10)-dien-11-acyloxyalkylenphenyl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten
EP3252069B1 (de) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentalfuoromethyl)estra-4,9-dien-3-one zur behandlung von krankheiten
EP1747229A1 (de) Steroid-prodrugs mit androgener wirkung
WO2013064620A1 (de) 18-METHYL-6,7-METHYLEN-3-OXO-17-PREGN-4-EN-21,17β-CARBOLACTONE, PHARMAZEUTISCHE PRÄPARATE ENTHALTEND DIE GENANNTEN VERBINDUNGEN UND DEREN ANWENDUNG BEI DER THERAPIE DER ENDOMETRIOSE
EP1525215B1 (de) Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
EP1747230A1 (de) Aminosulfonyl- oder aminosulfonylamino-substituierte phenyl-ester als estradiol-prodrugs
DE60030410T2 (de) Steroidsulfatase-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung
EP1747231A1 (de) Aminosulfonyl- oder aminosulfonylamino-substituierte phenyl-ester als estriol- und estetrol-prodrugs
DE10236405A1 (de) Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
EP1599493B1 (de) Antitumor wirksame 2-substituierte estra-1,3,5(10)-trien-3-yl sulfamate
DE60224982T2 (de) Androgenische 7-substituierte 11-halogenierte steroide
DE3402330A1 (de) 1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
EP1187846B1 (de) 11beta-langkettig-substituierte estratriene, verfahren zur herstellung, pharmazeutische präparate, die diese 11beta-langkettig-substituierten estratriene enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CH621560A5 (en) Process for the preparation of 3-ketosteroids disubstituted in position 16
DE2409436A1 (de) Steroid-(halogenalkyl)-nitroso-carbamat- und -allophanat-verbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US20050282793A1 (en) Steroid prodrugs with androgenic action
EP1737880B1 (de) 17 alpha-fluor 17 beta-hydroximinomethyl-steroide, ein verfahren zu deren herstellung und diese verbindung enthaltende pharmazeutische zusammensetzungen
WO2007062877A2 (de) PRODRUGS ERβ-SELEKTIVER SUBSTANZEN, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE VERBINDUNGEN ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN
EP0780397B1 (de) Neue 17alpha-Cyanomethylestra-4,9-dien-derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
WO2007062876A1 (de) Prodrugs er-beta-selektiver substanzen, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
DE2100319B2 (de) Neue Östranverbindungen, ihre Herstellung und sie enthaltende Arzneimittel
DE1618687A1 (de) Verfahren zur Herstellung von Steroid-acetalen,-hemithioacetalen und -thioacetalen
DE2311390A1 (de) 17-cyclooctenyloxysteroide, ihre verwendung und verfahren zur herstellung derselben
EP2773356A1 (de) 18-methyl-6,7-methylen-3-oxo-17-pregn-4-en-21,17 -carbolactone, pharmazeutische präparate enthaltend die genannten verbindungen und deren anwendung bei der therapie der endometriose

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8127 New person/name/address of the applicant

Owner name: BAYER SCHERING PHARMA AG, 13353 BERLIN, DE

8127 New person/name/address of the applicant

Owner name: BAYER SCHERING PHARMA AKIENGESELLSCHAFT, 13353, DE

8131 Rejection